As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...

Rates of hepatitis C virus (HCV) infections fell to 0.6% among gay and bisexual men living with HIV after a systematic HCV elimination campaign, showing that micro-elimination campaigns paired with ...

Please provide your email address to receive an email when new articles are posted on . Georgia’s hepatitis C virus elimination program made significant progress in helping diagnose patients and begin ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Please provide your email address to receive an email when new articles are posted on . Intent Solutions announced a partnership with the University of Kentucky in a $15 million federal grant program ...

Atea Pharmaceuticals, Inc. ( (AVIR)) has released its Q3 earnings. Here is a breakdown of the information Atea Pharmaceuticals, Inc. presented to its investors. Atea Pharmaceuticals, Inc. is a ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...

Dr. James W. Galbraith joined the University of Alabama at Birmingham (UAB) Emergency Medicine faculty in 2008. In 2011, Dr. Galbraith led the implementation of emergency department (ED) non-targeted, ...

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...